Tuberous sclerosis complex and the mTOR pathway
Explore this paper's citation graph
Summary
Increasing data are indicating that rapamycin is effective in various hamartomas in TSC patients, and therapeutic outcomes are encouraging so far.
- Type
- article
- Published
- 2011-01-01
- Cited by
- 0
- References
- 6
- OpenAlex
- https://openalex.org/W2186743590
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:86123083
Keywords
TSC2, TSC1, RHEB, Tuberous sclerosis, PI3K/AKT/mTOR pathway
References
- Do We Have a Cure for Tuberous Sclerosis Complex?
- Rapamycin Reduces Seizure Frequency in Tuberous Sclerosis Complex
- Rapamycin causes regression of astrocytomas in tuberous sclerosis complex
- Rapamycin and tuberous sclerosis complex: From Easter Island to epilepsy
- Recent advances in neurobiology of Tuberous Sclerosis Complex.
- mTOR signaling at a glance
Cited by
No citing papers recorded for this paper.
Related papers
- Mammalian target of rapamycin inhibitors for treat- ment in tuberous sclerosis
- Toward targeted treatments in tuberous sclerosis
- Finding a cure for tuberous sclerosis complex: From genetics through to targeted drug therapies.
- Tuberous sclerosis complex: From molecular biology to novel therapeutic approaches
- Role of TSC1 in physiology and diseases
- Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex
- Tuberous Sclerosis and Insulin Resistance: Unlikely Bedfellows Reveal A TORrid Affair
- Tuberous sclerosis--A model for tumour growth.
- Mammalian Target of Rapamycin Signaling and Autophagy